Maryam Banikazemi
Valhalla, NYNPI 1831164672
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $340,289 of the $519,192 with a category attached, or 65.5%. Sanofi accounts for 97.9% of it on its own, with 8 other manufacturers making up the rest.
Across 458 payments — averaging $1133.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$508K
- Rhythm Pharmaceuticals, Inc.$5K
- Chiesi USA, Inc.$4K
- Biomarin Pharmaceutical Inc.$656
- Amicus Therapeutics, Inc.$432
- Sanofi-aventis U.S. LLC$372
- plus $106 from 3 others
Across 64 payments — averaging $6150.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$306K
- Sanofi$66K
- Rhythm Pharmaceuticals, Inc.$22K
What the payments were for
- Consulting fees$105,25620%
- Speaking & faculty fees$340,28966%
- Travel & lodging$62,99712%
- Food & beverage$10,5902%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 416 | $508,125 |
| Rhythm Pharmaceuticals, Inc. | 9 | $5,430 |
| Chiesi USA, Inc. | 8 | $4,071 |
| Biomarin Pharmaceutical Inc. | 12 | $656 |
| Amicus Therapeutics, Inc. | 2 | $432 |
| Sanofi-aventis U.S. LLC | 7 | $372 |
| Ultragenyx Pharmaceutical Inc. | 2 | $60 |
| Pfizer | 1 | $26 |
| Adlon Therapeutics L.p. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FABRAZYME$392,987
- LUMIZYME$25,586
- CERDELGA$21,453
- NO PRODUCT DISCUSSED$9,934
- ALDURAZYME$7,499
- CEREZYME$7,499
- XENPOZYME$6,411
- NEXVIAZYME$6,318
- Imcivree$5,411
- FERRIPROX$943
- ELFABRIO$300
- LAMZEDE$104
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FabrazymeAgalsidase Beta | 48 | $658,498 |
| GalafoldMigalastat Hcl | 18 | $531,233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiFabrazyme | $508,125 | $658,49848 claims |
| Amicus Therapeutics, Inc.Galafold | $432 | $531,23318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in New Yorkon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.